Pronova, Apotex Strike Deal Over Generic Lovaza

Law360, New York (March 30, 2011, 5:28 PM EDT) -- Apotex Corp. on Tuesday agreed to hold off on manufacturing a generic version of Lovaza until 2015 to resolve Norwegian pharmaceutical company Pronova BioPharma Norge AS' patent infringement claims over the triglyceride-lowering drug.

In separate stipulations of dismissal without prejudice, the parties agreed to voluntarily drop Pronova's two infringement suits that were scheduled to begin the first phase of trial in the U.S. District Court for the District of Delaware on Tuesday, with each party bearing its own attorneys' fees and costs.

Although the stipulation did...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.